AI, NGS, and Mass Spectrometry Driving the Next Growth Wave in Genomics and Proteomics

 

The global genomics and proteomics reagents, research kits and analytical instruments market is entering a high-growth phase, fueled by technological innovation, expanding research investments, and the accelerating shift toward precision medicine. Valued at US$ 79.6 Bn in 2024, the market is projected to grow at a CAGR of 8.6% from 2025 to 2035, surpassing US$ 197.3 Bn by the end of 2035.

Analyst Perspective

The industry is witnessing rapid expansion as falling sequencing costs, advancements in mass spectrometry, and increased integration of artificial intelligence (AI) transform biological research. Genomics and proteomics tools are now central to understanding disease mechanisms, enabling targeted drug development, and supporting personalized treatment strategies. The rising global burden of chronic and hereditary diseases has further strengthened the need for high-throughput reagents, advanced research kits, and powerful analytical instruments.

Market Introduction

Genomics focuses on studying the complete DNA sequence of organisms, while proteomics examines protein structure, function, and interactions. Reagents and research kits—such as PCR reagents, antibodies, nucleotides, and protein assay kits—are essential components in laboratory workflows. Analytical instruments including next-generation sequencers, mass spectrometers, chromatography systems, and microarray platforms enable detailed molecular analysis.

These technologies are widely applied in diagnostics, oncology research, drug discovery, transcriptomics, and biomarker identification. For example, genomic sequencing identifies mutations critical for targeted cancer therapies, while proteomic profiling helps monitor treatment response and disease progression.

 

Get Sample PDF Copy: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=983

 

Key Market Drivers

Technological Innovations in Sequencing and Mass Spectrometry

Advancements in next-generation sequencing (NGS) technologies have significantly reduced the time and cost of genomic analysis. NGS platforms allow researchers to conduct whole-genome and single-cell sequencing at unprecedented scale and precision. Companies such as Illumina, Inc. continue to push the boundaries of sequencing efficiency and throughput.

Similarly, innovations in liquid chromatography-mass spectrometry (LC-MS) have revolutionized proteomics research. High-resolution mass spectrometry systems from companies like Bruker enable sensitive protein quantification and post-translational modification analysis.

Automation and integration with bioinformatics platforms further enhance reproducibility and throughput, supporting large-scale clinical and pharmaceutical research.

Rising Demand for Personalized Medicine

Precision medicine is transforming healthcare delivery by tailoring treatments based on genetic and molecular profiles. Government initiatives such as the National Institutes of Health Precision Medicine programs have significantly accelerated genomic research funding.

In oncology, genomic tumor profiling helps identify actionable mutations, leading to targeted therapies with improved outcomes. Proteomics complements this approach by identifying biomarkers associated with drug response, enabling clinicians to refine treatment protocols.

Segment Insights

The Reagents and Research Kits segment holds a dominant market share due to its indispensable role in experimental workflows. Ready-to-use kits enhance efficiency, reduce procedural variability, and support reproducibility across laboratories. Growth in NGS and mass spectrometry adoption further boosts demand for high-quality reagents and consumables.

Regional Outlook

North America led the market in 2024, supported by strong biotechnology infrastructure, high R&D investments, and favorable funding programs. The region benefits from collaborations between academic institutions and industry leaders such as Thermo Fisher Scientific Inc. and Agilent Technologies, Inc..

Asia Pacific is emerging as a high-growth region, driven by expanding pharmaceutical manufacturing, genomic research initiatives, and increasing healthcare investments in countries like China and India.

Competitive Landscape

Leading players in the market include Thermo Fisher Scientific Inc., Merck KGaA, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, 10x Genomics, and BGI Genomics.

Recent innovations highlight the dynamic nature of the industry. In July 2025, QIAGEN N.V. launched QIAseq xHYB Long Read Panels to support complex genomic region analysis. In April 2025, Standard BioTools Inc. introduced advanced proteomic solutions including SomaScan Select 3.7K Assay and CyTOF XT PRO system at a major oncology conference.

Future Outlook

With continuous advancements in high-throughput sequencing, mass spectrometry, automation, and AI-driven analytics, the genomics and proteomics reagents, research kits and analytical instruments market is poised for sustained expansion. As precision medicine becomes mainstream and global research collaborations intensify, demand for innovative molecular tools will continue to rise, driving the market beyond US$ 197.3 Bn by 2035.